Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1875 Target Snapshot

5-hydroxytryptamine receptor 4 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,096Compounds
297Assays
8Approved Drugs
1,174.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

5-hydroxytryptamine receptor 4 shows approved-linked disease relevance led by Constipation. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q13639. Start with Constipation, then reuse UniProt Q13639 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Constipation, then reuse UniProt Q13639 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 4 linked drugs
Open source guide
Disease program
Constipation

5-hydroxytryptamine receptor 4 shows approved-linked disease relevance led by Constipation. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with Constipation because it currently carries approved-linked support. Linked drugs include MOSAPRIDE, PRUCALOPRIDE, PRUCALOPRIDE SUCCINATE, RELENOPRIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 4 as ChEMBL target CHEMBL1875, mapped to UniProt Q13639. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1875
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13639
5-hydroxytryptamine receptor 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 5-hydroxytryptamine receptor 4 is the right protein anchor across sources, using UniProt Q13639 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Constipation is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name5-hydroxytryptamine receptor 4
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ13639
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label5-hydroxytryptamine receptor 4
UniProt AccessionQ13639
Component TypeProtein
Sequence Length388 aa

5-hydroxytryptamine receptor 4

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as 5-hydroxytryptamine receptor 4, mapped to UniProt Q13639. Sequence length is 388 aa.

Mapped IDQ13639
Review name5-hydroxytryptamine receptor 4
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

5-hydroxytryptamine receptor 4 shows approved-linked disease relevance led by Constipation. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
Constipation
4 linked drugs · 4 direct · 4 efficacy
Linked drugMOSAPRIDE
Linked drugPRUCALOPRIDE
Linked drugPRUCALOPRIDE SUCCINATE
Linked drugRELENOPRIDE
Approved-linked Approved
gastroparesis
4 linked drugs · 4 direct · 4 efficacy
Linked drugFELCISETRAG
Linked drugMETOCLOPRAMIDE HYDROCHLORIDE
Linked drugNARONAPRIDE
Linked drugVELUSETRAG
Approved-linked Approved
irritable bowel syndrome
4 linked drugs · 4 direct · 4 efficacy
Linked drugMOSAPRIDE
Linked drugPRUCALOPRIDE
Linked drugRENZAPRIDE
Linked drugTEGASEROD MALEATE
Approved-linked Approved
constipation disorder
2 linked drugs · 2 direct · 2 efficacy
Linked drugPRUCALOPRIDE SUCCINATE
Linked drugTEGASEROD MALEATE
Approved-linked Approved
gastrointestinal disease
2 linked drugs · 2 direct · 2 efficacy
Linked drugCLEBOPRIDE
Linked drugMOSAPRIDE
Approved-linked Approved
Anorexia
1 linked drug · 1 direct · 1 efficacy
Linked drugMETOCLOPRAMIDE HYDROCHLORIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Constipation because it currently carries approved-linked support. Linked drugs include MOSAPRIDE, PRUCALOPRIDE, PRUCALOPRIDE SUCCINATE, RELENOPRIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseConstipation
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

8
Approved
4
Phase III
9
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC5092.0
KI630.0
EC50449.0
KD3.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL180835 10.8 Ki 0.01585 Preclinical
CHEMBL68131 10.8 Ki 0.01585 Preclinical
CHEMBL181202 10.6 Ki 0.02512 Preclinical
CHEMBL361118 10.6 Ki 0.02512 Preclinical
CHEMBL367354 10.5 Ki 0.03162 Preclinical
CHEMBL181126 10.5 Ki 0.03162 Preclinical
CHEMBL182999 10.5 Ki 0.03162 Preclinical
CHEMBL3967117 10.41 IC50 0.039 Preclinical
CHEMBL33884 10.4 Ki 0.03981 Preclinical
CHEMBL2181170 10.4 Ki 0.03981 Preclinical
Distribution

pChEMBL Value Distribution

28
5.0
43
5.5
60
6.0
97
6.5
149
7.0
179
7.5
168
8.0
122
8.5
92
9.0
52
9.5
pChEMBL
Approved Drugs

Approved Drugs

PRUCALOPRIDE
CHEMBL117287
Approved 2009
Properties Compare Identifier
TEGASEROD
CHEMBL76370
Approved 2002
Properties Compare Identifier
CISAPRIDE
CHEMBL1729
Approved 1993
Properties Compare Identifier
METOCLOPRAMIDE
CHEMBL86
Approved 1979
Properties Compare Identifier
Assay Landscape

Assay Landscape

297
Total Assays
659
Tested Compounds
4
Assay Types
Binding — 210 assays, 659 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 120 155 7.9
cell-based format 77 463 7.8
assay format 9 40 7.6
cell membrane format 2 1 8.0
tissue-based format 2 0 —
Functional — 85 assays, 259 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 59 214 8.0
assay format 17 43 8.0
single protein format 6 1 7.7
tissue-based format 3 1 6.1
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 0 —
Unassigned — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine